Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | FNTA | P49354 | 2/20 | 0.31 |
| ▸ | FNTB | P49356 | 2/20 | 0.31 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097299 | 0.80 | CYP19A1 (0.42) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL13160969 | 0.79 | CYP11B1 (0.50) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL6252365 | 0.79 | BACE1 (0.44) | BACE1 | |
| SCHEMBL1106690 | 0.75 | — | — | |
| SCHEMBL6602683 | 0.73 | SIGMAR1 (0.42) | — | |
| SCHEMBL3628808 | 0.70 | CYP11B1 (0.60) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL6598797 | 0.70 | FNTA (0.48) | FNTAFNTBPGGT1B | |
| SCHEMBL3463864 | 0.69 | FNTA (0.47) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL1096475 | 0.69 | CYP19A1 (0.41) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL1040990 | 0.69 | CYP11B1 (0.39) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153674-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-20090182007-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182007-A1 | ORGANIC COMPOUNDS | REN, CYP17A1, HSD17B1 | BACE1 1709/4885CYP11B1 12/4885CYP11B2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.